Skip to main content
. Author manuscript; available in PMC: 2009 Jul 6.
Published in final edited form as: Am J Physiol Endocrinol Metab. 2007 Dec 4;294(2):E392–E400. doi: 10.1152/ajpendo.00582.2007

Fig. 5.

Fig. 5

p70 ribosomal S6 kinase 1 (S6K1) and eukaryotic elongation factor-2 (eEF2). All subjects were treated identically during baseline, exercise, and 1 h postexercise. One-half of the subjects ingested a leucine-enriched EAA+CHO solution at the end of the first hour of postexercise recovery [2 h post (EAA+CHO)] compared with control subjects [2 h post (control)]. A: S6K1 phosphorylation and total S6K1. B: eEF2 phosphorylation and total eEF2. Data are means ± SE. *P < 0.05 vs. baseline. Insets show representative blots for the loading control and for each time point.